IL-12 engineering in anti-Nectin-4 CAR-T cells has progressed to a phase I clinical trial against Nectin-4 + solid tumors (NCT03932565), as well as with anti-MUC16ecto CAR-T cells against ovarian cancers (NCT02498912), and with anti-EGFR CAR-T cells against metastatic colorectal cancer (NCT03542799), all ongoing. This evidence concerns the gene NECTIN4 and metastatic colorectal cancer.